Thursday, December 20, 2012 9:19:45 AM
DVAX
OB, no disrespect. Everyone is entitled to a opinion however I have to disagree with you.
DVAX being able to fix the safety issues before the next schedule FDA review has nothing to do with how DVAX will trade. The fact that there is even a 1 in a million chance that it could be approved will cause the usual FDA run-up, It's just the way things are.
It's all about the catalysis and DVAX has a good one. Cramer has already said not to sell at this level and he expects a rebound leading up to the next round with the FDA. I'm not saying he's right or wrong, what I'm saying is the fact that he even mentioned DVAX has "traders" salivating over the possibilities.
Approval or disapproval has nothing to do with what happens before the announcement.
Let's look at a recent FDA approval and see how it effected the stocks PPS.
Last Friday we saw a bearish move in shares of Ariad Pharmaceuticals NASDAQ: ARIA) on news that its drug Iclusig (ponatinib) was approved early by the FDA.
OB, no disrespect. Everyone is entitled to a opinion however I have to disagree with you.
DVAX being able to fix the safety issues before the next schedule FDA review has nothing to do with how DVAX will trade. The fact that there is even a 1 in a million chance that it could be approved will cause the usual FDA run-up, It's just the way things are.
It's all about the catalysis and DVAX has a good one. Cramer has already said not to sell at this level and he expects a rebound leading up to the next round with the FDA. I'm not saying he's right or wrong, what I'm saying is the fact that he even mentioned DVAX has "traders" salivating over the possibilities.
Approval or disapproval has nothing to do with what happens before the announcement.
Let's look at a recent FDA approval and see how it effected the stocks PPS.
Last Friday we saw a bearish move in shares of Ariad Pharmaceuticals NASDAQ: ARIA) on news that its drug Iclusig (ponatinib) was approved early by the FDA.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
